High Fasting Blood Glucose Level With Unknown Prior History of Diabetes Is Associated With High Risk of Severe Adverse COVID-19 Outcome

Abstract

BackgroundWe aimed to understand how glycaemic levels among COVID-19 patients impact their disease progression and clinical complications.MethodsWe enrolled 2,366 COVID-19 patients from Huoshenshan hospital in Wuhan. We stratified the COVID-19 patients into four subgroups by current fasting blood glucose (FBG) levels and their awareness of prior diabetic status, including patients with FBG<6.1mmol/L with no history of diabetes (group 1), patients with FBG<6.1mmol/L with a history of diabetes diagnosed (group 2), patients with FBG≥6.1mmol/L with no history of diabetes (group 3) and patients with FBG≥6.1mmol/L with a history of diabetes diagnosed (group 4). A multivariate cause-specific Cox proportional hazard model was used to assess the associations between FBG levels or prior diabetic status and clinical adversities in COVID-19 patients.ResultsCOVID-19 patients with higher FBG and unknown diabetes in the past (group 3) are more likely to progress to the severe or critical stage than patients in other groups (severe: 38.46% vs 23.46%-30.70%; critical 7.69% vs 0.61%-3.96%). These patients also have the highest abnormal level of inflammatory parameters, complications, and clinical adversities among all four groups (all p<0.05). On day 21 of hospitalisation, group 3 had a significantly higher risk of ICU admission [14.1% (9.6%-18.6%)] than group 4 [7.0% (3.7%-10.3%)], group 2 [4.0% (0.2%-7.8%)] and group 1 [2.1% (1.4%-2.8%)], (P<0.001). Compared with group 1 who had low FBG, group 3 demonstrated 5 times higher risk of ICU admission events during hospitalisation (HR=5.38, 3.46-8.35, P<0.001), while group 4, where the patients had high FBG and prior diabetes diagnosed, also showed a significantly higher risk (HR=1.99, 1.12-3.52, P=0.019), but to a much lesser extent than in group 3.ConclusionOur study shows that COVID-19 patients with current high FBG levels but unaware of pre-existing diabetes, or possibly new onset diabetes as a result of COVID-19 infection, have a higher risk of more severe adverse outcomes than those aware of prior diagnosis of diabetes and those with low current FBG levels.

Association of ABO blood group with respiratory disease hospitalization and severe outcomes: a retrospective cohort study in blood donors

“…The result is contradicting the findings regarding COVID-19 that group O has a lower risk. It may imply that there is more complexity and sus-ceptibility of the COVID-19 disease compared with previous pneumonia (Kong et al, 2021;Wang et al, 2021) . Only one study has proposed the possible mechanisms underlying the association.…”

Low- and middle-income countries demonstrate rapid growth of type 2 diabetes: an analysis based on Global Burden of Disease 1990–2019 data

“…In many developed countries, including Scotland [ 6 ], Canada [ 7 ], UK [ 8 ], Denmark [ 9 ], Sweden [ 10 ], Australia [ 11 ] and USA [ 12 ], type 2 diabetes-related mortality has declined steadily. People living with type 2 diabetes are at higher risk of chronic diseases, viral hepatitis and even COVID-19 severity [ 13 – 16 ]. However, large developing economies such as China reported an ongoing and increasing trend of diabetes mellitus, with diabetes mortality increasing from 5.3 deaths/100,000 people in 1990 to 10.9 deaths/100,000 people in 2017 [ 17 ].…”

Malnutrition management of hospitalized patients with diabetes/hyperglycemia and COVID-19 infection

“…If the screening and/or nutritional assessment cannot be carried out, and given that patients with diabetes/ hyperglycemia and COVID-19 have high probabilities of presenting or developing malnutrition during hospitalization, assuming malnutrition may be an appropriate approach [38]. Even more, it may be advisable to screen and monitor glycemic and nutritional status during the routine evaluation of all COVID-19 patients, as elevated blood glucose levels predicted worse outcomes in hospitalized patients [39].…”